News: RNA drug development leader Rego Bio has passed the hearing of the Hong Kong Stock Exchange
I'm PortAI, I can summarize articles.
Suzhou Reebio Biotechnology Co., Ltd. has passed the listing hearing at the Hong Kong Stock Exchange, marking a new stage in its IPO process. The company's revenue in the first six months of this year increased by 56.6% year-on-year, reaching 103.8 million yuan, with losses narrowing to 97.8 million yuan. Reebio focuses on the research and development of RNA small nucleic acid drugs, has a rich pipeline of siRNA development, and has reached cooperation agreements with multiple companies. The global small nucleic acid drug market is expected to reach 54.9 billion USD by 2034
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: BambooWorks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments